Extended Data Fig. 8: Clinical implication of the anti-C-E-cad antibody in vivo. (Related to Fig. 8).
a, In vivo tumorigenicity assay using GSC4121 treatment with Nimotuzumab (N_mab), anti-C-E-cad antibodies or in combination, (n = 10 animals). BLI images (Left) indicated brain BITC tumor xenografts. Right, IHC of p-EGFR expression in indicated GSC tumours, scale bar, 250μm (n = 3 animals). b, Left, Relative intensity of fluorescent index of BLI that indicate tumor growth of GSC4121 brain tumor xenografts in animals treated with Nimotuzumab (N_mab), anti-C-E-cad antibodies or in combination. Data were presented as mean ± SD, two-sided t test, ***p < 0.001. Middle, Two-sided, Log-rank analysis of mice treated with indicated therapeutic strategies. Right, P values were calculated, n = 10 animals. c, In vivo tumorigenicity assay using GSC387 and 4121 and treatment with Laptinib, anti-C-E-cad antibodies or in combination. BLI images at different time point, (n = 10 animals). d, Left: Relative intensity of fluorescent index of BLI that indicate tumor growth of GSC387 and 4121 brain tumor xenografts in animals treated with Laptinib (1 μg/μl, 3 μl), anti-C-E-cad antibodies or in combination, n = 10 animals. Data were presented as mean ± SD, two-sided t test, ***p < 0.001.Middle, Two-sided, Log-rank analysis of mice treated with indicated therapeutic strategies. Right, P values were calculated, (n = 10 animals).
